Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Werner Hoellriegl
Observed names:
W. HOELLRIEGL,
W. Hoellriegl
Institution:
Takeda (Austria)
Observed institutions:
University of Vienna,
Baxter (Austria),
Takeda (Austria)
OpenAlex ID:
A5030164422
A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13
2012
·
Alexandra Schiviz
, Kuno Wuersch
, et al.
·
Blood
·
135
Towards a standardization of the murine tail bleeding model
2010
·
T.K. GREENE
, A. SCHIVIZ
, et al.
·
Journal of Thrombosis and Haemostasis
·
99
Porcine recombinant factor VIII (Obizur; OBI ‐1; BAX 801): product characteristics and preclinical profile
2015
·
D. Lillicrap
, A. Schiviz
, et al.
·
Haemophilia
·
37
Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive In Vitro Assays
2019
·
Anita Kruzik
, Herwig Koppensteiner
, et al.
·
Human Gene Therapy Methods
·
32
Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease
2022
·
Paolo Rossato
, Enrica Federti
, et al.
·
Haematologica
·
24
PDF
Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency
2020
·
Wenjing Cao
, Biao Dong
, et al.
·
Molecular Therapy — Methods & Clinical Development
·
21
PDF
Development of an In Vitro Biopotency Assay for an AAV8 Hemophilia B Gene Therapy Vector Suitable for Clinical Product Release
2020
·
Johannes Lengler
, Sogue Coulibaly
, et al.
·
Molecular Therapy — Methods & Clinical Development
·
19
PDF
Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B
2013
·
Barbara Dietrich
, Alexandra Schiviz
, et al.
·
International Journal of Hematology
·
16
PDF
Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell disease
2023
·
Paolo Rossato
, Helmut Glantschnig
, et al.
·
Journal of Thrombosis and Haemostasis
·
11
PDF
Pharmacokinetics of BAX 826, a Polysialylated Full-Length rFVIII, in Hemophilia a Mice, Rats, and Cynomolgus Monkeys
2015
·
Alexandra Schiviz
, Gerald Hoebarth
, et al.
·
Blood
·
6
Development of BAX 826, a Polysialylated Full-Length rFVIII with Significantly Improved PK Properties
2015
·
Peter L. Turecek
, Juergen Siekmann
, et al.
·
Blood
·
4
Pharmacokinetics of Baxter’s Longer Acting rFVIII (BAX 855) in Factor VIII Ko Mice, Rats and Cynomolgus Monkeys
2011
·
Gerald Hoebarth
, Susan Kubik
, et al.
·
Blood
·
3
Preclinical development of TAK-754, a high-performance AAV8-based vector expressing coagulation factor VIII
2025
·
Johannes Lengler
, Markus Weiller
, et al.
·
Molecular Therapy — Methods & Clinical Development
·
2
Nonclinical Safety of SHP 826 (BAX 826), a Next Generation Extended Half-Life Recombinant Factor VIII Product
2016
·
Veronika Ehrlich
, Peter Leidenmuehler
, et al.
·
Blood
·
2
A TFPI Inhibitory Half Life Extended Fusion Peptide Proves Efficacy in FVIII Knock out Mice and Marmoset Monkeys
2014
·
Michael Dockal
, Rudolf Hartmann
, et al.
·
Blood
·
2
Preclinical Efficacy Testing of Baxter's Recombinant ADAMTS13 in a Mouse Model of TTP.
2012
·
Alexandra Schiviz
, Marlene Resch
, et al.
·
Blood
·
2
AAV8-Specific Immune Adsorption Column: A Treatment Option for Patients with Pre-Existing Anti-AAV8 Neutralizing Antibodies
2019
·
Anita Kruzik
, Roland Raim
, et al.
·
Blood
·
1
Lethality of Mouse Tissue Factor Pathway Inhibitor Gene Disruption Is Rescued By Transgenic Human Tissue Factor Pathway Inhibitor Knock in
2015
·
Robert Pachlinger
, Rudolf Hartmann
, et al.
·
Blood
·
1
Impact of Factor IXa Content On Function, Safety and Efficacy of Recombinant Factor IX Products.
2012
·
Wilfried Auer
, Hanspeter Rottensteiner
, et al.
·
Blood
·
1
Peptides Inhibiting Tissue Factor Pathway Inhibitor Improve Hemostasis in Mice
2011
·
Michael Dockal
, Rudolf Hartmann
, et al.
·
Blood
·
1
The Factor VIII Variant X5 Enhances Hemophilia a Gene Therapy Efficiency By Its Improved Secretion
2019
·
Franziska Horling
, Johannes Lengler
, et al.
·
Blood
Influence of Obesity on Factor IX Expression after Gene Therapy in a Mouse Model of Hemophilia B
2017
·
Sogué Coulibaly
, Markus Weiller
, et al.
·
Blood
Development of SHP648, Shire's high performing AAV8-based FIX gene therapy vector
2017
·
Frank Horling
, Falko G. Falkner
, et al.
·
Human Gene Therapy
Nonclinical Assessment of Bax 604 (FEIBA STAR) - Reduced Volume Reconstitution & Higher Infusion Rate
2016
·
Gerald Hoebarth
, Alexandra Kopic
, et al.
·
Blood
Concomitant Administration Of Activated Prothrombin Complex Concentrate and Recombinant Activated Factor VII At Low Doses Are Efficacious and Safe In Hemophilic Mice
2013
·
Michael Dockal
, Sabine Knappe
, et al.
·
Blood
Show more works
View as search
Works count:
28
Citation count:
419
H-index:
9
I10-index:
9
Year
Topic
Type